Novartis /
Regulus Therapeutics Inc.
Novartis completes its acquisition of Regulus Therapeutics Inc.
What happened
Novartis completed its acquisition of Regulus Therapeutics Inc. on June 25, 2025. Regulus is now an indirect wholly owned subsidiary of Novartis.
The tender offer provided $7.00 in cash per Share, plus one contingent value right per Share.
The source
Everything on this page comes from the source below.
Novartis completes its acquisition of Regulus Therapeutics Inc.
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly